We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




‘Glow-In-The-Dark’ Proteins to Help Diagnose Viral Diseases More Quickly and Easily

By LabMedica International staff writers
Posted on 16 Mar 2023
Print article
Image: Proteins that glow bright blue or green could make disease diagnosis quicker and easier (Photo courtesy of Eindhoven University of Technology)
Image: Proteins that glow bright blue or green could make disease diagnosis quicker and easier (Photo courtesy of Eindhoven University of Technology)

Despite undergoing technological advancements, most diagnostic tests for viral diseases that are highly sensitive still involve complex techniques to prepare a sample or interpret the results, making it hard to administer these tests in point-of-care settings or in locations with limited resources. Now, a team of researchers has come up with a sensitive technique that analyzes viral nucleic acids in as little as 20 minutes and can be finished in one step using “glow-in-the-dark” proteins.

Bioluminescence is a scientific phenomenon caused by a chemical reaction involving the luciferase protein that creates the luminescent, glow-in-the-dark effect. The luciferase protein has been utilized in creating sensors that emit observable light when they detect their target, making them perfect for point-of-care testing. Nonetheless, these sensors lack the high levels of sensitivity required of a clinical diagnostic test. A gene-editing method known as CRISPR has shown promise in providing this ability, although it requires multiple steps and additional specialized instruments to detect low signals from a complex and noisy sample. So, researchers at Eindhoven University of Technology (Eindhoven, Netherlands) aimed to use CRISPR-related proteins, but combine them with a bioluminescence technique whose signal could be detected with only a digital camera.

In order to ensure that there were sufficient RNA or DNA samples for analysis, the scientists employed recombinase polymerase amplification (RPA), which is a straightforward technique that operates at a constant temperature of around 100 F. The researchers devised a new technique, LUNAS (luminescent nucleic acid sensor), that is comprised of two CRISPR/Cas9 proteins specific for different neighboring parts of a viral genome each have a distinct fragment of luciferase attached to them. Upon detecting the presence of a specific viral genome being tested, the two CRISPR/Cas9 proteins bind to the designated nucleic acid sections and are drawn close to one another, enabling the complete luciferase protein to form and shine blue light in the presence of a chemical substrate.

To take into account the depletion of the substrate, the researchers utilized a control reaction that radiated green light. The presence of a positive result was indicated by a tube that changed from green to blue. The RPA-LUNAS technique successfully detected SARS-CoV-2 RNA in clinical samples obtained from nasal swabs in just 20 minutes, even at concentrations as low as 200 copies per microliter. The researchers believe that the LUNAS assay holds immense potential for quickly and efficiently detecting various other viruses.

Related Links:
Eindhoven University of Technology 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crystal Light/Shutterstock)

New AI Tool Classifies Brain Tumors More Quickly and Accurately

Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.